Integra LifeSciences Holdings Corporation IART
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About IART
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Integra LifeSciences Holdings Corporation is a U.S.-based medical technology company that develops, manufactures, and markets medical devices, implants, biologics, and surgical instruments used primarily in neurosurgery, wound care, reconstructive surgery, and related specialties. The company operates within the broader healthcare and medical devices industry, serving hospitals, surgical centers, clinicians, and healthcare systems globally. Its principal revenue drivers include neurosurgical products, regenerative tissue technologies, advanced wound care solutions, and surgical instrumentation platforms. Integra has developed a strong position in specialty surgical markets where procedural complexity, clinical outcomes, and surgeon preference create high barriers to entry.
The company traces its origins to 1989 and has expanded through internal product development and acquisitions. Integra evolved from a regenerative medicine-focused business into a diversified surgical and specialty medical technology company through acquisitions such as Codman Neurosurgery assets from Johnson & Johnson and ACell, Inc. The company’s strategic positioning centers on specialized clinical categories, surgeon-focused innovation, and a portfolio spanning both implantable technologies and surgical tools. Public disclosures in SEC filings and company investor materials consistently identify neurosurgery and tissue technologies as core strategic pillars.
Business Operations
Integra organizes operations primarily through two major business segments: Codman Specialty Surgical and Tissue Technologies. Codman Specialty Surgical includes neurosurgery, neurocritical care, instruments, and related specialty surgical products, while Tissue Technologies focuses on regenerative tissue products, advanced wound care, and reconstructive solutions. Revenue is generated through direct product sales to hospitals and healthcare providers, distributor arrangements in certain international markets, and recurring procedural utilization of its medical technologies.
The company maintains manufacturing, research, and commercial operations across North America, Europe, and selected Asia-Pacific markets. Integra controls a portfolio of proprietary regenerative tissue technologies, neurosurgical systems, cranial stabilization products, dural repair products, and surgical instrumentation assets. Major subsidiaries and acquired businesses include Codman Neurosurgery, ACell, Inc., and various specialty surgical operations integrated into its broader platform. The company also maintains strategic commercial relationships with healthcare providers and distributors to support international expansion and procedural adoption.
Strategic Position & Investments
Integra’s strategic direction has focused on expanding higher-margin specialty surgical categories, strengthening regenerative tissue technologies, and improving operational execution following manufacturing and quality remediation efforts disclosed in public filings. Growth initiatives have included expanding the neurosurgery portfolio, increasing penetration in advanced wound care, and investing in surgeon training and procedural adoption programs. Company disclosures and investor presentations indicate a continued emphasis on operational efficiency, supply chain reliability, and targeted innovation in specialty care markets.
The company has historically pursued acquisitions to deepen its product portfolio and clinical capabilities. Notable transactions include the acquisition of ACell, Inc., which strengthened regenerative medicine and wound care capabilities, and the acquisition of neurosurgical assets from Johnson & Johnson that became central to the Codman Specialty Surgical segment. Integra has also invested in product development related to tissue regeneration, cranial reconstruction, hydrocephalus management, and advanced surgical instrumentation. Publicly available information indicates ongoing involvement in biologic implants, regenerative matrices, and technologies supporting complex surgical procedures.
Geographic Footprint
Integra LifeSciences is headquartered in Princeton, New Jersey, and operates across multiple international regions through direct operations and distribution networks. The company has a significant presence in North America, which represents its largest market, while also maintaining commercial and operational activities in Europe, Asia-Pacific, Latin America, and parts of the Middle East. Its products are used in hospitals and surgical centers worldwide, particularly in developed healthcare systems with advanced neurosurgical and reconstructive care capabilities.
International operations include manufacturing sites, sales offices, and distribution partnerships supporting specialty surgical and regenerative technologies. The company’s global footprint is designed to support both mature healthcare markets and selected growth regions where demand for advanced surgical care continues to expand. Public filings and investor disclosures confirm operational exposure across numerous countries, although revenue concentration remains strongest in the United States and other developed medical device markets.
Leadership & Governance
Integra LifeSciences is governed by a board of directors and executive leadership team with backgrounds in medical devices, healthcare operations, finance, and regulatory management. Corporate strategy has emphasized specialty market leadership, disciplined portfolio management, product innovation, and quality system improvement. Leadership communications in earnings materials and SEC filings have consistently highlighted operational execution, patient safety, regulatory compliance, and long-term value creation through focused medical technology categories.
Key executives include:
- Mojdeh Poul – President and Chief Executive Officer
- Glenn Coleman – Senior Vice President and Chief Financial Officer
- Robert T. Davis – Executive Chairman
- Dawn Z. Carter – Senior Vice President, General Counsel and Corporate Secretary
- Jodi Toleno – Senior Vice President, Global Quality and Regulatory Affairs
Publicly available governance documents indicate that the company emphasizes compliance oversight, quality management, disciplined capital allocation, and strategic specialization in complex surgical markets. Leadership commentary across investor communications has consistently reinforced the importance of innovation, surgeon engagement, and operational reliability as central components of Integra’s long-term strategy.